Important Presentations from the SABCS 2024 Press Briefings
- Next-generation SERD Protects Against Progression in Some Patients With Advanced Breast Cancer Resistant to Standard Hormone Therapy
- BRCA-mutation Carriers With a History of Early-onset Breast Cancer May Benefit From Risk-reducing Surgery
- PARP Inhibition Shows Long-term Survival Benefits for Patients With High-risk, BRCA-positive Breast Cancer in OlympiA Trial
- Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients with ‘Good-risk’ DCIS Who Forgo Radiation
- Most Patients With Intermediate-risk Breast Cancer May Safely Avoid Chest Wall Irradiation After Mastectomy
- COMET Trial Finds Active Monitoring Is a Viable Option for Some Patients With Low-risk DCIS
- Palbociclib added to anti-HER2 plus ET, a new standard of care for patients diagnosed with HR+ HER2+ advanced breast cancer
- HR-positive, HER2-negative Breast Cancer Patients With High Risk of Recurrence May Benefit From Addition of Anthracyclines to Taxane-based Chemotherapy
- Multimodal Machine Learning Model Effective at Predicting Response to CDK4/6 Inhibitors in HR-positive, HER2-negative Breast Cancer Patients
- ZEST Trial Offers Insights for Using ctDNA to Predict Breast Cancer Recurrence
Next-generation SERD Protects Against Progression in Some Patients With Advanced Breast Cancer Resistant to Standard Hormone Therapy
GS1-01: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and Combined
with Abemaciclib, for Patients with ER+, HER2- Advanced Breast Cancer (ABC), Pretreated with Endocrine
Therapy (ET): Results of the Phase 3 EMBER-3 trial
More info about study
Recorded @ SABCS 2024, December 11
SLIDES Courtesy [Presenting Author]
Published in NEJM: Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
BRCA-mutation Carriers With a History of Early-onset Breast Cancer May Benefit From Risk-reducing Surgery
GS1-08: Association between risk-reducing surgeries and survival in young BRCA carriers with breast
cancer: results from an international cohort study
More INFO about Study
Recorded @ SABCS 2024, December 11
SLIDES Courtesy Presenting Author
PARP Inhibition Shows Long-term Survival Benefits for Patients With High-risk, BRCA-positive Breast Cancer in OlympiA Trial
GS1-09: OlympiA - Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after
(neo)adjuvant chemotherapy in patients w/ germline BRCA1/BRCA2 pathogenic variants & high risk HER2-
negative primary breast cancer; longer term follow
More INFO about Study
Recorded @ SABCS 2024, December 11
Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients with ‘Good-risk’ DCIS Who Forgo Radiation
GS2-02: Impact of Tamoxifen Only after Breast Conservation Surgery for "Good Risk" Duct Carcinoma in
Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial
More INFO about Study
Recorded @ SABCS 2024, December 12
SLIDES Courtesy Presenting Author
Most Patients With Intermediate-risk Breast Cancer May Safely Avoid Chest Wall Irradiation After Mastectomy
GS2-03: Does postmastectomy radiotherapy in 'intermediate-risk' breast cancer impact overall survival? 10
year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators
More INFO about Study
Recorded @ SABCS 2024, December 12
SLIDES Courtesy [Presenting Author]
COMET Trial Finds Active Monitoring Is a Viable Option for Some Patients With Low-risk DCIS
GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25)
More INFO about Study
Recorded @ SABCS 2024, December 12
SLIDES Courtesy [Presenting Author]
Palbociclib added to anti-HER2 plus ET, a new standard of care for patients diagnosed with HR+ HER2+ advanced breast cancer
GS2-12 – AFT-38 PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor-Positive (HR+)/HER2-Positive Metastatic Breast Cancer
More INFO about Study
Recorded @ SABCS 2024, December 12
SLIDES Courtesy [Presenting Author]
HR-positive, HER2-negative Breast Cancer Patients With High Risk of Recurrence May Benefit From Addition of Anthracyclines to Taxane-based Chemotherapy
GS3-03: Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer
More INFO about Study
Recorded @ SABCS 2024, December 13
SLIDES Courtesy [Presenting Author]
Multimodal Machine Learning Model Effective at Predicting Response to CDK4/6 Inhibitors in HR-positive, HER2-negative Breast Cancer Patients
GS3-09: Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors
outcomes in patients with HR+/HER2- metastatic breast cancer
Recorded @ SABCS 2024, December 13
ZEST Trial Offers Insights for Using ctDNA to Predict Breast Cancer Recurrence
GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib
or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular
residual disease after definitive therapy
Recorded @ SABCS 2024, December 13